Paediatric Department, Hospital Universitari Arnau de Vilanova [Arnau de Vilanova University Hospital], Lleida, Spain.
Paediatric Neurology Department, Hospital Materno-Infantil Vall d'Hebron [Vall d'Hebron Maternity-Neonatal Hospital], Barcelona, Spain.
Epilepsy Behav. 2020 Jun;107:107067. doi: 10.1016/j.yebeh.2020.107067. Epub 2020 Apr 14.
The primary objective of the study was to analyze the efficacy of brivaracetam (BRV) in pediatric patients 12 months after starting treatment. The secondary objective was to establish safety 3, 6, and 12 months after starting treatment.
This was an observational and retrospective study. Data were collected from the electronic medical record. Inclusion criteria were as follows: patients under 18 years of age, diagnosis of focal or generalized epilepsy, treatment as an added therapy, initiation of treatment with BRV between June and September 2017, and at least one unprovoked seizure in the year prior to the start of treatment.
Forty-six patients were included. The response rate was 65%, including 30% seizure-free patients. The rate of adverse effects was 43.5%, resulting in withdrawal in 16 patients (34.7%). The most common adverse effects were drowsiness (17.3%) and irritability (17.3%).
Brivaracetam is effective in very diverse childhood epilepsies, including some that present with primarily generalized seizures. Given the characteristics of the population studied, we have not been able to confirm a better tolerability of BRV compared with levetiracetam (LEV).
本研究的主要目的是分析开始治疗 12 个月后布瓦西坦（BRV）在儿科患者中的疗效。次要目的是在开始治疗后 3、6 和 12 个月建立安全性。
这是一项观察性和回顾性研究。数据从电子病历中收集。纳入标准如下：年龄在 18 岁以下，诊断为局灶性或全面性癫痫，作为附加疗法治疗，在 2017 年 6 月至 9 月期间开始 BRV 治疗，且在治疗开始前一年至少有一次无诱因发作。
共纳入 46 例患者。应答率为 65%，包括 30%的无癫痫发作患者。不良反应发生率为 43.5%，导致 16 例患者（34.7%）停药。最常见的不良反应是嗜睡（17.3%）和易怒（17.3%）。
BRV 对非常不同的儿童癫痫有效，包括一些主要表现为全面性发作的癫痫。鉴于所研究人群的特点，我们还不能确认 BRV 的耐受性优于左乙拉西坦（LEV）。
